Sign up Australia
Proactive Investors - Run By Investors For Investors

MaxCyte appoints biotech pioneer as independent director

Richard Douglas was senior vice president of corporate development and corporate officer at Genzyme Corporation from 1989 until its sale to Sanofi in 2011
boardroom table
There will be a new face around the boardroom table

MaxCyte PLC (LON:MXCT) has appointed a new independent director who brings with him three decades’ of experience in the life sciences industry gleaned working with one of the pioneers of biotechnology.

He is Richard Douglas, who was senior vice president of corporate development and corporate officer at Genzyme Corporation from 1989 until its sale to Sanofi in 2011.

READ: MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

During this period he led numerous acquisitions, licences, financings, joint ventures and strategic alliances.

He currently serves as an advisor to RedSky Partners, a biotechnology-focused advisory firm.

Wealth of experience

MaxCyte chief executive Doug Doerfler said: “Richard's wealth of expertise in business and corporate development and his deep life sciences industry experience will bring invaluable perspective to the MaxCyte board.

"We are extremely pleased to have Richard as part of our organisation as we further our enablement of new medicines in the areas of gene editing and immuno-oncology, and move our first product candidate from our CARMA therapeutic platform into the clinic."

MaxCyte describes itself as a global cell-based medicines and technology company.

CARMA the bedrock of the business 

It has developed a technology called CARMA which is funded from its income and cash reserves.

This is being deployed to tackle cancer and it is hoped the platform will be spawn the next-generation immuno-oncology treatments that use the body’s own immune system to fight the disease.

What’s new and innovative, even for this very new and innovative strand of research, is that CARMA is being designed to grapple with solid tumours.

The breakthroughs in this field, such as CAR T-cell immuno-therapies, fight blood-borne illness, and yet 90% of cancers are solid tumours.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018
Article
October 10 2018

Related Articles

Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use